Interpretation of Reverse Payment Patent Settlement and Antitrust Laws in Pharmaceutical Industries
Year: 2024
Type: article
Abstract: The idea of Reverse Payment Settlement came into the limelight after the essential features of the Patent holder came into the forefront. It has recently gained prominence due to the challenges that have arisen due to the ongoing uncertainty and unfair advantage the inventor, patent holder, or the corporation has gained by participating in anti-competitive and antitrust policies. It is vital to understand the history and meaning of the reverse payment patent settlement to properly comprehend what it implies and what might comprise such agreements. It also discusses why the parties have reached such agreements and what they signify. The article mainly describes the competitive policies of the USA on Reverse payment patent settlement via the ANDA and the principle it gave rise to by implementation or suspension of the generic business from creating a specific product and engaging the entity via monetary payment. The payment will be equal to the period during which the generic company's production is hampered and the cost incurred due to the litigation. As a result, it is a reverse payment or an exception, as an infringement usually pays the patent holder. The pharmaceutical sector creates many issues due to the miscarriage of competitive policies in drugs and medicines. We are all aware that access to health care is the most important policy issue for communities. The industry's therapeutic value typically defines it and the rationality it is marketed. Due to new drugs in the market and their exclusivity period from the generic medicines sold, accessibility became one of the prime concerns in the pandemic period. As covid-19 hit the world's hard right to get healthcare, fundamental rights are being violated. So, in this article, the author will explain the need for a regulatory system in the country by way of specific guidelines to ensure that these techniques do not impede competition in the country. With it, the economy at large, which is affected at first examination, it is evident that when it comes to the general public's healthcare, cannot to extend the exclusivity provided by patented pharmaceuticals for drug corporations' unilateral economic motivations. The article discusses the value and necessity of a policy framework and the challenges of applying and implementing these words. The impact on India and its competition is significant.
Authors: Aranya Nath, Usha Saha
Institution: GITAM University
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
OpenAlex ID: W7216631253